Generalized Anxiety Disorder: A Persistent Burden and a New Look at Psychedelics

A Common Condition That Carries a High Burden

Generalized anxiety disorder ranks among the most prevalent psychiatric conditions, with a past-year prevalence near 10% of US adults.¹ GAD is chronic and recurrent, and the functional toll is heavy, with impairment across work, social, and physical domains, reductions in quality of life comparable to those seen in major depression, and higher medical costs than in patients without the disorder.² Comorbidity magnifies the burden, with mood and other anxiety disorders frequently accompanying the diagnosis.

Standard Treatments With Incomplete Results

SSRIs and SNRIs remain the foundation of pharmacologic care, but their efficacy is less than ideal. In a network meta-analysis of double-blind randomized trials, first-line agents such as duloxetine, escitalopram, paroxetine, and venlafaxine roughly doubled the odds of remission compared with placebo (odds ratios of about 1.7 to 2.3), ³ yet roughly half of patients have an inadequate response to first-line treatment.⁴ Therapeutic options have also stalled, with no new pharmacotherapy approved for GAD in the US market since 2007.⁵

What Real-World Prescribing Reveals

A 2026 real-world analysis of US insurance claims covering 259,158 newly diagnosed and 1,018,288 established patients with GAD underscores the gap.⁶ SSRIs were the most common treatment class (45% of newly diagnosed and 51% of established patients), followed by benzodiazepines and other antidepressants, with benzodiazepine use markedly higher in established disease (33% versus 22%). Approximately 25% of newly diagnosed patients had no pharmacotherapy claim in the 12 months after diagnosis.

Where Standard Care Falls Short

Standard pharmacotherapy helps many patients but leaves many others symptomatic, and the absence of a mechanistically new approval for nearly two decades limits what clinicians can offer those who do not respond. That gap is pushing the field toward a markedly different approach. Serotonergic psychedelics, long outside mainstream psychiatry, are being formally evaluated in generalized anxiety disorder, including a lysergide-based agent tested in a recent randomized, placebo-controlled trial.⁵ How these compounds work, and whether their benefits prove durable, is now a question of keen interest to researchers, clinicians, and patients alike.

References

1. Ringeisen H, Edlund M, Guyer H, et al. Mental and Substance Use Disorders Prevalence Study (MDPS): findings report. RTI International; 2023.
2. Revicki DA, Travers K, Wyrwich KW, et al. Humanistic and economic burden of generalized anxiety disorder in North America and Europe. J Affect Disord. 2012;140(2):103-112.
3. Kong W, Deng H, Wan J, et al. Comparative remission rates and tolerability of drugs for generalised anxiety disorder: a systematic review and network meta-analysis of double-blind randomized controlled trials. Front Pharmacol. 2020;11:580858.
4. Ansara ED. Management of treatment-resistant generalized anxiety disorder. Ment Health Clin. 2020;10(6):326-334.
5. Robison R, Barrow R, Conant C, et al. Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial. . 2025;334(15):1358-1372.
6. Louie D, Ferries E, Suponcic S, et al. Treatment patterns among newly diagnosed patients with generalized anxiety disorder and patients with established GAD: insights from real-world evidence. Poster presented at: ASCP Annual Meeting; 2026.